Batch of Anti-Anxiety Drug Xanax Recalled, F.D.A. Says
The New York Times • • business
Key Points:
- The FDA has announced a recall of a single lot of 3 mg extended-release Xanax XR tablets distributed nationwide due to concerns that the tablets may not dissolve properly, potentially affecting drug absorption and effectiveness.
- The recalled lot, labeled 8177156 with an expiration date of February 28, 2027, was distributed in 60-pill bottles between August 2024 and May 2025; Viatris reported no adverse events and considers the risk to patients negligible.
- The recall affects only this specific lot of Xanax XR; no other doses, batches, or generic versions of alprazolam are impacted.
- Pharmacies are instructed to remove the affected medication from their shelves, but patients are advised not to take any action without consulting their healthcare provider.
- Xanax is a benzodiazepine used to treat anxiety and panic disorders, known for its calming effects and potential for addiction.
